Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )
ClinicalTrials.gov Identifier:
NCT00118131
First received: July 8, 2005
Last updated: September 19, 2013
Last verified: September 2013

July 8, 2005
September 19, 2013
December 2003
February 2010   (final data collection date for primary outcome measure)
Overall Tumor Response Rate [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Patients experiencing complete or partial response
Not Provided
Complete list of historical versions of study NCT00118131 on ClinicalTrials.gov Archive Site
  • Time to Progressive Disease [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • 1-year Survival Rate [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Median Survival Time [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherapy-Naive Patients With Stage IV or Select Stage IIIB (Malignant Effusion) Non-Small Cell Lung Cancer

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel together with cisplatin works in treating patients with stage III or stage IV non-small cell lung cancer.

OBJECTIVES:

Primary

  • Determine the antitumor activity of docetaxel and cisplatin, as measured by tumor response rate, in patients with chemotherapy-naïve stage IIIB or IV non-small cell lung cancer.

Secondary

  • Determine the duration of response in patients treated with this regimen.
  • Determine time to disease progression in patients treated with this regimen.
  • Determine the 1-year survival rate in patients treated with this regimen.
  • Determine the median survival time in patients treated with this regimen.
  • Correlate aneuploidy (as determined by DNA histograms) and immunohistochemical expression of stathmin, Aurora-A, and survivin with response in patients treated with this regimen.

OUTLINE: This is an open-label, nonrandomized, multicenter study.

Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour once on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within 13-19 months.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
  • Drug: cisplatin
  • Drug: docetaxel
Experimental: Docetaxel and Cisplatin

A cycle is defined as an interval of 28 days.

Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).

Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).

Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.

Interventions:
  • Drug: cisplatin
  • Drug: docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
49
February 2010
February 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed non-small cell lung cancer, meeting 1 of the following stage criteria:

    • Stage IIIB disease with malignant pericardial or malignant pleural effusions, as indicated by 1 of the following:

      • Positive cytology
      • Exudative effusion AND lactic dehydrogenase (LDH) > 200 IU with effusion/serum LDH ratio ≥ 0.6
    • Stage IV disease
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion > 20 mm by conventional techniques OR > 10 mm by spiral CT scan
  • Brain metastases allowed provided they have been irradiated AND are radiographically stable for ≥ 28 days after the completion of radiotherapy

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL

Hepatic

  • AST and ALT normal
  • Bilirubin normal

Renal

  • Creatinine clearance ≥ 50 mL/min

Immunologic

  • No known HIV positivity
  • No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • No clinically significant active infection

Other

  • Not pregnant or nursing
  • Fertile patients must use effective contraception before, during, and for 4 weeks after completion of study treatment
  • No other primary malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No other serious systemic disorder that would preclude study participation
  • No other condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Prior antibody-based therapy that targets growth factor pathways (e.g., epidermal growth factor receptor [EGFR]) allowed provided there is disease progression during therapy and patient has recovered
  • No concurrent immunotherapy
  • No concurrent prophylactic colony-stimulating factors
  • No concurrent interleukin-11

Chemotherapy

  • No prior cytotoxic chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • No concurrent hormonal therapy for the malignancy

Radiotherapy

  • See Disease Characteristics
  • More than 28 days since prior radiotherapy and recovered
  • No prior radiotherapy to ≥ 25% of the bone marrow
  • No prior radiotherapy to sites of measurable disease unless there is documented tumor progression after completion of radiotherapy
  • No concurrent radiotherapy

Surgery

  • No concurrent surgery for the malignancy

Other

  • More than 3 weeks since prior investigational drugs
  • Prior oral small molecule drug therapy that targets growth factor pathways (e.g., EGFR) allowed provided there is disease progression during therapy and patient has recovered
  • No other concurrent investigational or commercial agents or therapies for the malignancy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00118131
CDR0000433488, P30CA072720, CINJ-030302, CINJ-NJ1503
No
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )
University of Medicine and Dentistry of New Jersey
  • National Cancer Institute (NCI)
  • Aventis Pharmaceuticals
Principal Investigator: Joseph Aisner, MD Rutgers Cancer Institute of New Jersey
Rutgers, The State University of New Jersey
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP